25th Feb 2014 11:11
LONDON (Alliance News) - Omega Diagnostics Group PLC said Tuesday that it had received a backdated patent for its CD4 test in 15 of the African Regional International Property Organisation States.
The patent is valid from July 24, 2013.
Omega produces Visitect CD4, a disposable, semi-quantitative rapid test for the determination of CD4 counts in whole blood. CD4+ T-cells are destroyed by the HIV virus, so monitoring their count is important for the management of HIV patients being treated by antiretroviral drug therapies.
Shares in Omega were trading up 6.7% at 32.55 pence Tuesday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright © 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
ODX.L